Keymed’s Stapokibart Drug Advances with Priority Review

Keymed Biosciences, Inc. (HK:2162) has released an update.

Keymed Biosciences Inc. has announced that their new drug application for Stapokibart injection, aimed at treating chronic rhinosinusitis with nasal polyps, has been accepted and granted priority review by the National Medical Products Administration. The application follows a successful phase III clinical trial, where the drug met all primary endpoints and demonstrated significant efficacy and a favorable safety profile. Stapokibart is a pioneering IL-4R α antibody treatment, with potential applications in other conditions such as atopic dermatitis and seasonal allergic rhinitis.

For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.